RecruitingNCT05060783

Renal Cancer Detection With Liquid Biopsy


Sponsor

Zealand University Hospital

Enrollment

200 participants

Start Date

Jul 1, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

Glycosaminoglycans (GAGs) were significantly altered in localized as well advanced RCC compared to healthy samples. In addition, GAG scores correlated with progression-free survival and overall survival (OS) in a prospective cohort of patients with metastatic ccRCC and localized RCC. However, it is still unknown whether alterations in plasma and urine GAGs are exquisitely specific to RCC or are shared by other benign lesions in the kidney, such as angiomyolipomas, oncocytomas, or PEComa.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Patients who underwent CT-scan with suspicion of renal tumor and the scans show no sign of renal cancer.
  • For patient with ccRCC or oncocytoma, they should have a histological verified tumor (Biopsy or surgical specimen)
  • Sign up information consent
  • Can perform protocol procedure

Exclusion Criteria3

  • Non-clear cell Renal cell carcinoma
  • RCC with pure sarcomatoid differentiation, also called sarcoma of the kidney
  • Use of heparin for concurrent disease in need of blood dilution (e.g. ongoing deep vein thrombosis or lung emboli). Note: use of of heparin for thrombus prophylaxis in conjunction with primary surgery or postoperatively ≤4 weeks will be allowed.

Interventions

DIAGNOSTIC_TESTGaGnostic

Plasma

DIAGNOSTIC_TESTGaGnostic

Serum

DIAGNOSTIC_TESTGaGnostic

Urine


Locations(1)

Zealand University Hospital

Roskilde, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05060783


Related Trials